Western Regional Blog – BC, YK, AB, NWT and Nunavut
“The research … found that the 10-gene biomarker panel may identify the aggressiveness of a patient’s disease, help predict survival outcomes and result in novel therapeutic strategies tailored to patients with the most adverse survival outcomes.”
Researchers in the Women’s Cancer Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.
The research, led by Dong-Joo (Ellen) Cheon, PhD, found that the 10-gene biomarker panel may identify the aggressiveness of a patient’s disease, help predict survival outcomes and result in novel therapeutic strategies tailored to patients with the most adverse survival outcomes.
When a patient’s tumor is identified as having elevated levels of these 10 specific genes, doctors may be able to better predict which treatments would be most effective, said Cheon, whose research was published in Clinical Cancer Research.
That is an important advance because ovarian cancer is the most lethal gynecologic cancer and is often diagnosed in later, more aggressive stages, resulting in poor prognosis and survival. These outcomes differ due to development of tumors that become resistant to chemotherapy. By identifying chemo-resistant tumors and identifying the risk of poor survival outcomes during the diagnostic process, investigators hope to extend lives and improve treatment responses for women with ovarian cancer.
“The ultimate goal is to use the 10-gene biomarker panel to develop a diagnostic kit that will identify patients with the most adverse outcome and provide targeted therapeutic strategies,” said Cheon.
“Among the biomarkers identified, the gene COL11A1 was shown to be the most abundantly expressed in ovarian cancer progression. But when we blocked expression of COL11A1 in murine cancer cells, tumor growth and spread was significantly reduced.”